Φορτώνει......
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
BACKGROUND: A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemo...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Prev Cardiol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7735387/ https://ncbi.nlm.nih.gov/pubmed/26229089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2047487315598709 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|